CTOs on the Move

Liquidia Technologies

www.liquidia.com

 
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.liquidia.com
  • PO Box 110085
    Research Triangle Park, NC USA 27709
  • Phone: 919.328.4400

Executives

Name Title Contact Details

Funding

Liquidia Technologies raised $22.4M on 12/26/2019

Similar Companies

Acrometrix

Acrometrix is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.

Priovant Therapeutics

Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

Sherlock Biosciences

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.